Skip to main content

Table 1 pre-operative baseline data

From: Safety and efficacy of Holmium laser enucleation of the prostate (HoLEP) in patients with previous transperineal biopsy (TPB): outcomes from a dual-centre case-control study

  Group 1 Group 2 Difference (95% CI) p value
Age (years) 66.8 (±8.2) 71.8 (±8.7) 5.0 (1.2, 8.9) 0.012
TRUS volume (cm3) 76.1 (±35.0) 69.3 (±31.8) 8.5 (−24.1, 10.6) 0.402
PSA (ng/mL) 10.2 (±5.7) 5.0 (±3.9) 5.1 (2.5, 7.8) < 0.001
Indication for HoLEP
 LUTS 11 (45.8%) 34 (40.0%) 5.8 (−15.0, 27.3) 0.644
 Refractory retention 13 (54.2%) 51 (60.0%)   
Qmax (mL/sec) 9.9 (±4.3) 9.6 (±5.2) 0.4 (−3.0, 3.8) 0.817
PVR (mL) 181.4 (±99.6) 176.8 (±140.3) 4.6 (− 77.5, 86.8) 0.908
IPSS 22.4 (±4.7) 22.6 (±6.9) 0.2 (−3.7, 4.0) 0.923
Quality of life score 4.1 (±1.0) 4.4 (±1.2) 0.3 (−0.5, 1.1) 0.484
Serum creatinine (μmol/L) 81.0 (±16.0) 86.7 (±30.3) 5.7 (−3.5, 15.0) 0.219
  1. CI Confidence intervals, TRUS Trans-rectal ultrasound, PSA Prostate specific antigen, HoLEP Holmium laser enucleation of the prostate, LUTS Lower urinary tract symptoms, Qmax maximum flow rate, PVR Post-void residual volume, IPSS International Prostate Symptom Score. Data presented as mean (SD) except *counts (%).